SemaThera is a biotechnology startup that originated as a spin-off from AmorChem Fund 1. Founded in 2016 and headquartered in Canada, the company's primary focus is on a cutting-edge target, semaphorin 3A (SEMA3A). SemaThera is dedicated to developing bispecific SEMA3A / VEGF inhibitors (traps) designed to address the issue of vascular leakage and inflammation in diabetic macular edema (DME). This technology specifically targets the 30% of DME patients who do not respond well to current anti-VEGF therapies. As of 26 March 2018, SemaThera received a significant $2.60M Venture Round investment led by Amorchem and Senju Pharmaceutical. The company's unique positioning and innovative approach to addressing an unmet need in the biotechnology space make it an intriguing prospect for potential investors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $2.60M | 2 |
|
26 Mar 2018 |
| Seed Round | $1.00M | - | 12 Jan 2017 |
No recent news or press coverage available for SemaThera Inc.
We care about your data, and we'd love to use cookies make your experience better.
